Lassa mammarenavirus

IMUNON Reports 2023 Financial Results and Provides Business Update

Retrieved on: 
Giovedì, Marzo 28, 2024
Transfer, Ovarian cancer, Immunotherapy, Patient, Lung, Vaccine, Good manufacturing practice, Sale, CMC, IND, Bangladesh Technical Education Board, IPR, Investment, Clinical trial, Neoplasm, Research, Primate, DNA, NOL, MD Anderson Cancer Center, Trial of the century, ITT, Safety, MRD, Interim, Silicon Valley Bank, Vaccination, Food, CMOS, Elsevier, CD8, Drug discovery, SVB, CRS, University, Death, SARS-CoV-2, Earnings call, Lassa mammarenavirus, PFS, Immunoglobulin G, FDA, OS, CD4, Temperature, Progression-free survival, COVID-19, Mouse, Messenger, Human, Wistar Institute, Hospital

LAWRENCEVILLE, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today reported financial results for the year ended December 31, 2023. The Company also provided an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary mono- or multi-cistronic DNA plasmid and a synthetic DNA delivery technology for the expression of pathogen antigens in preclinical studies for the development of next-generation vaccines.

Key Points: 
  • “We remain on track to report topline results mid-year from the OVATION 2 Study with IMNN-001 in advanced ovarian cancer.
  • In September 2023, the Company announced interim PFS and OS data with IMNN-001 in its OVATION 2 Study.
  • The Company is hosting a conference call to provide a business update, discuss 2023 financial results and answer questions at 10:00 a.m. Eastern time today.
  • To participate in the call, please dial 866-777-2509 (Toll-Free/North America) or 412-317-5413 (International/Toll) and ask for the IMUNON 2023 Earnings Call.

Primmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction Agency (DTRA) to Advance PRTX007 for Treatment of Lassa Fever

Retrieved on: 
Mercoledì, Marzo 20, 2024
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, DTRA, Conditional sentence, Inflammation, Viral, Marburg virus disease, Human, TLR7, Therapy, Lassa mammarenavirus, Lassa fever, Bleeding, Toll-like receptor 7, Vaccine

Primmune Therapeutics , a biotech company harnessing the power of the innate immune system, today announced that it was awarded a $22,480,552 contract by the Defense Threat Reduction Agency (DTRA) to develop PRTX007 as an oral broad spectrum antiviral TLR7 agonist for the treatment of Lassa fever.

Key Points: 
  • Primmune Therapeutics , a biotech company harnessing the power of the innate immune system, today announced that it was awarded a $22,480,552 contract by the Defense Threat Reduction Agency (DTRA) to develop PRTX007 as an oral broad spectrum antiviral TLR7 agonist for the treatment of Lassa fever.
  • The objective of the program is to evaluate the efficacy of PRTX007 in a series of animal models for Lassa fever and establish an effective treatment method of Lassa virus in humans.
  • “Primmune has demonstrated broad spectrum antiviral activity with PRTX007 and with related compounds from our discovery and development program,” said Charlie McDermott, President, Chief Executive Officer and Director of Primmune Therapeutics.
  • “PRTX007’s novel immunologic approach has the potential for combination use with direct acting anti-viral agents – enabling widely applicable utility in the treatment of Lassa fever and other hemorrhagic viruses.”

IMUNON’s Chief Science Officer to Present at the 3rd International Vaccines Congress

Retrieved on: 
Lunedì, Ottobre 23, 2023
FDA, Food, SARS-CoV-2, Human, Omicron, Vaccine, Science, Immune system, COVID-19, Lassa mammarenavirus, Messenger, Kinetics, Infection, Shenzhen Kangtai Biological Products, Bangladesh Technical Education Board, Safety, Wistar Institute, Cancer, International Vaccine Institute, Drug discovery, DNA, Pharmaceutical industry

LAWRENCEVILLE, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company focused on harnessing the power of the immune system against cancer and infectious diseases, announces that Khursheed Anwer, Ph.D., IMUNON’s executive vice president and chief science officer, will highlight the Company’s vaccine development work at the 3rd International Vaccines Congress being held in Boston October 23-26.

Key Points: 
  • Dr. Anwer will present “A DNA-based Vaccine Technology Independent of Virus or Device,” at 2:00 p.m. Eastern time on October 23rd.
  • His presentation describes the multiple advantages of the Company’s PlaCCine modality over current commercial vaccine platforms, including more durable antigen expression and T-cell responses versus protein and mRNA vaccines.
  • Compared with viral or other DNA vaccines or protein vaccines, PlaCCine vaccines have advantages in T-cell responses, safety, compliance and manufacturing flexibility.
  • “We are delighted to share our ongoing work at this important conference,” said Dr. Corinne Le Goff, president and chief executive officer of IMUNON.

IMUNON Enters into CRADA for Preclinical Studies of PlaCCine Modality in Preventive Vaccines Against Lassa Virus

Retrieved on: 
Giovedì, Agosto 24, 2023
National Institute of Allergy and Infectious Diseases, CRADA, Research, Lassa mammarenavirus, Development, Death, Incidence, Cooperative research and development agreement, Developed country, Risk, Lassa fever, NIAID, Laboratory, Infection, World Health Organization, Vaccine, Virology

LAWRENCEVILLE, N.J., Aug. 24, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, announces it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate the immunogenicity and efficacy of two IMUNON DNA-based Lassa virus vaccine candidates. Under the three-year agreement, the NIAID will assess the efficacy of PlaCCine DNA constructs against Lassa virus in guinea pig and non-human primate disease models, including both prime and prime-boost vaccine strategies.

Key Points: 
  • Under the three-year agreement, the NIAID will assess the efficacy of PlaCCine DNA constructs against Lassa virus in guinea pig and non-human primate disease models, including both prime and prime-boost vaccine strategies.
  • Lassa virus is typically spread by rodents and can cause Lassa fever, a viral hemorrhagic-fever disease that is a significant and growing public health concern with approximately 5,000 deaths annually.
  • Nearly 60 million people throughout West Africa are estimated to be at risk of contracting Lassa fever.
  • Because of its lethality and increasing incidence, NIAID and the World Health Organization have categorized Lassa virus as a Category A Priority Pathogen.

CEPI Boosts ‘Coronavirus X’ Vaccine Search With Expanded VBI Vaccines Deal

Retrieved on: 
Martedì, Dicembre 6, 2022
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, Nipah virus, Interim, Coalition for Epidemic Preparedness Innovations, Infection, Disease, Government of Canada, COVID-19, G7, Risk, Chikungunya, Cytomegalovirus, Virus, National Research Council, Partnership, Coronavirus, Epidemic, Multimedia, Vaccine, COVID-19 vaccine, Severe acute respiratory syndrome coronavirus 2, Glioblastoma, Middle East respiratory syndrome–related coronavirus, Omicron, Hepatitis B, Lassa mammarenavirus, Science, VLP, CEPI, CMV, Severe acute respiratory syndrome coronavirus, Immunity, Nature, COVAX, Immune system, NRC, Rift Valley fever, Pandemic, Research, Annual report, Human coronavirus 229E, Public sector, VBI, News, Safety, G20, GBM, Coalition, Animal, Pharmaceutical industry

The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its world-leading portfolio of potential variant-proof coronavirus vaccines in a deal with VBI Vaccines Inc. (Nasdaq: VBIV) to advance the development of multivalent coronavirus shots that could be deployed against COVID-19 as well as a future Coronavirus X.

Key Points: 
  • The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its world-leading portfolio of potential variant-proof coronavirus vaccines in a deal with VBI Vaccines Inc. (Nasdaq: VBIV) to advance the development of multivalent coronavirus shots that could be deployed against COVID-19 as well as a future Coronavirus X.
  • Application of this funding will now be directed into the broader development of the VBI-2900 coronavirus vaccine program to explore the Coronavirus X potential of VBIs technology.
  • We have long recognized the public health value that multivalent vaccines capable of anticipating new variants and coronavirus strains could provide.
  • VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease.

SK bioscience and CEPI Sign Agreement to Develop mRNA Vaccines

Retrieved on: 
Martedì, Ottobre 25, 2022
Lassa mammarenavirus, Bill, RNA transfection, Pandemic, Second, CEPI, GIA, Virus, CMV, Ministry of Health and Welfare (South Korea), JEV, Vaccine, Organization, Foundation, RSV, SK, RNA, MOHW, Equitable, Partnership, Technology, Infection, Epidemic, Company, Public health, Health, CEO, Ministry, Park Min-soo, Coalition, Control, COVID-19, USD, Policy, Pharmaceutical industry

USD for early development of mRNA vaccine platform to SK bioscience; up to a further 100 mil.

Key Points: 
  • USD for early development of mRNA vaccine platform to SK bioscience; up to a further 100 mil.
  • Under the agreement, SK bioscience will receive up to 140 million USD in R&D expenses from CEPI.
  • Earlier, SK bioscience had the partnership with the Bill & Melinda Gates Foundation in order to build the mRNA vaccine platform.
  • CEPI and SK bioscience are committed to enabling global equitable access to the vaccines they develop.

Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate

Retrieved on: 
Martedì, Settembre 6, 2022
U.S. Department of Commerce Office of Security, Spleen, Public health, Human, Food, RNA, Safety, National Institute, NYSE, Program, Research, Government, Liver, Sierra Leone, Infection, Vaccine, Disease, Solution, Feces, Risk, SVP, LinkedIn, CEPI, National Institute of Allergy and Infectious Diseases, VSV, NIH, SEC, RATS, EBS, National Institutes of Health, Coalition for Epidemic Preparedness Innovations, National, Emergent BioSolutions, Lassa fever, GLOBE, Office of Inspector General, U.S. Department of Health and Human Services, Emergent, Instagram, Lassa mammarenavirus, Yale University, Therapy, Emergency, Twitter, NIAID, Nursing, Knowledge, Marketing, Licensure, Open access, Private Securities Litigation Reform Act, Urine, Life, Pharmaceutical industry

GAITHERSBURG, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study evaluating the safety and immunogenicity of EBS-LASV, a recombinant VSV-vectored Lassa virus vaccine candidate being developed for prevention of disease caused by Lassa virus infection.

Key Points: 
  • GAITHERSBURG, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study evaluating the safety and immunogenicity of EBS-LASV, a recombinant VSV-vectored Lassa virus vaccine candidate being developed for prevention of disease caused by Lassa virus infection.
  • This Phase 1 study, a randomized, placebo-controlled, dose-escalation study, will evaluate the safety and immunogenicity of Emergents rVSV-vectored Lassa virus vaccine in approximately 36 healthy adults at the Navrongo Health Research Centre and Kintampo Health Research Centre in Ghana.
  • Lassa virusa single-stranded RNA virus belonging to the family Arenaviridaecan cause the acute viral hemorrhagic illness known as Lassa fever.
  • In 2018, Emergent acquired development rights to the Profectus Lassa vaccine candidate now named EBS-LASV.

CEPI and Codiak BioSciences partner to develop broadly protective Betacoronavirus vaccine

Retrieved on: 
Martedì, Luglio 5, 2022
Coalition, LinkedIn, CEO, Epidemic, Biology, COVID, Vaccine, GLOBE, R, Infection, COVID-19, Disease, Ragon Institute, U.S. Securities and Exchange Commission, COVAX, Exosome, Davos, Partnership, Security (finance), B cell, Severe acute respiratory syndrome coronavirus 2, Private Securities Litigation Reform Act, Antigen, Rift Valley fever, Human coronavirus 229E, Nipah virus, Virus, Policy, Coalition for Epidemic Preparedness Innovations, RBD, NASDAQ, Middle East respiratory syndrome–related coronavirus, CEPI, Immunity, News, APC, Lassa mammarenavirus, Program, Coronavirus, Collaboration, Pharmaceutical industry, Chikungunya

CEPI will provide seed funding of up to US $2.5 million to Codiak BioSciencesa clinical-stage biopharmaceutical company based in Cambridge, MA, USAto continue the advancement of vaccine candidates from its pan Betacoronavirus program through preclinical studies.

Key Points: 
  • CEPI will provide seed funding of up to US $2.5 million to Codiak BioSciencesa clinical-stage biopharmaceutical company based in Cambridge, MA, USAto continue the advancement of vaccine candidates from its pan Betacoronavirus program through preclinical studies.
  • Dr Richard Hatchett, CEO of CEPI said: The COVID pandemic is not over and the R&D job is not done.
  • Initiating the development of broadly protective coronavirus vaccines should be an integral part of the worlds long-term strategy out of this pandemic.
  • CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines against future epidemics.

CEPI to co-fund Vaxxinity’s pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants

Retrieved on: 
Mercoledì, Aprile 6, 2022
Private Securities Litigation Reform Act, Risk, Pandemic, Conditional sentence, Vaccine, Research, Ageing, CEO, AstraZeneca, Technology, Nipah virus, Nasdaq, GLOBE, Efficiency, Annual report, University, Security (finance), COVAX, Epidemic, Coalition for Epidemic Preparedness Innovations, Vaccination, Disease, Pregnancy, Health, Immune system, Severe acute respiratory syndrome coronavirus 2, Omicron, U.S. Securities and Exchange Commission, Policy, Coalition, Amyris (company), Gaps, Clinical trial, Coronavirus, Migraine, Hypercholesterolemia, Immunity, Lassa mammarenavirus, Pfizer, Davos, COVID-19 vaccine, Patient, Partnership, Company, LinkedIn, CEPI, Chikungunya, Entrepreneurship, Immunodeficiency, Rift Valley fever, Safety, COVID-19, Human coronavirus 229E, News, Pharmaceutical industry, Developing country, Sinovac Biotech, DALLAS

Details on the Phase 3 UB-612-305 clinical trial can be found at clinicaltrials.gov using Identifier NCT05293665 .

Key Points: 
  • Details on the Phase 3 UB-612-305 clinical trial can be found at clinicaltrials.gov using Identifier NCT05293665 .
  • Approximately 1,000 healthy adults will take part in the Vaxxinity-sponsored multi-center international trial, with the first subjects already dosed in the US.
  • If successful, this trial may enable global authorizations, including in high income countries and LMICs.
  • This CEPI-supported trial will generate additional evidence to inform booster strategies in people previously vaccinated with vaccines distributed through COVAX, including against variants of concern.

Virus-Like Particles (VLP's) Market Research Report 2021: Forecast to 2028 with COVID-19 Impact and Global Analysis - ResearchAndMarkets.com

Retrieved on: 
Mercoledì, Gennaio 26, 2022
Infectious Diseases, Pharmaceutical, Health, COVID-19, Hepatitis, Food and Drug Administration, Coronavirus, Virus-like particle, PTM, Severe acute respiratory syndrome coronavirus, Therapy, Hepatitis C, HPV, HCV, Orthohantavirus, Government, RNA, Population, HBV, Cervarix, Chikungunya, VLP, FDA, Consistency, Virus, Hepatitis B, Growth, SARS, Incidence, Hepatitis B virus, Food, Hepatitis B Foundation, Mutation, Frontiers, A-DNA, Gaucher, Gaucher's disease, Safety, CAGR, DNA, Vaccine, Lassa mammarenavirus, Gardasil

The "Virus-like Particles (VLP's) Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Virus-like Particles (VLP's) Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.
  • However, the feasibility of VLPs as antigen carriers is questionable and complicated due to associated difficulties which is resulting in the sluggish growth of the global market.
  • The global virus-like particles (VLP's) market is segmented based on product type, source, and application.
  • Based on product type, the virus-like particles market is segmented as hepatitis, cancer/HPV, and Gaucher disease.